Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access |
Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc |
Journal website http://www.gastrores.org |
Review Article
Volume 4, Number 4, August 2011, pages 162-167
Biotherapy in the Adjuvant Treatment of Colorectal Cancer
Tables
Variable | NASBP C-08 | AVANT |
---|---|---|
Abbreviations: FOLFOX = infusional 5-fluorouracil/leucovorin/oxaliplatin; NSABP = National Surgical Adjuvant Breast and Bowel Project; XELOX = capecitabine/oxaliplatin. | ||
Number of arms | 2 | 3 |
Chemotherapy regimen | mFOLFOX 6 | FOLFOX 4, XELOX |
Maintenance Bevacizumab | 5 mg/Kg every 2 weeks | 7.5 mg/Kg every 3 weeks |
Analysis | Stage II and III | Stage III |
Regimen | Stage II | Stage II-III | Stage III |
---|---|---|---|
Abbreviations: BCTU = Birmingham Clinical Trials Unit; ECOG = Eastern Cooperative Oncology Group; FOxTROT = Fluoropyrimidine, Oxaliplatin, and Targeted Receptor Pre-Operative Therapy; NSABP = National Surgical Adjuvant Breast and Bowel Project. | |||
Chemotherapy +/- Bevacizumab | ECOG E5202 | NASBP C-08 AVANT QUASAR 2 TOSCA (IDEA) | _ |
Chemotherapy +/- Cetuximab | _ | _ | PETACC8 NO147 |
Chemotherapy +/- Panitumumab | _ | BCTU-FOxTROT | _ |